Brind.
  1. The Icahn School of Medicine at Mount Sinai is part of the Mount Sinai Health System.
  2. Miriam Merad leads the NYC-Vita clinical trial team as the Icahn School of Medicine at Mount Sinai integrates clinical trials and research enterprise.

FDA granted De Novo clearance for VitaSmart™ HOPE System, while Don Webber serves as CEO and President.

2 reports, 2 independent Updated Aug 12
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

FDA granted De Novo clearance for VitaSmart™ HOPE System, while Don Webber serves as CEO and President.

Who's involved

What this event is mainly about
FDAcompany

Keep exploring

Part of

Miriam Merad leads the NYC-Vita clinical trial team as the Icahn School of Medicine at Mount Sinai integrates clinical trials and research enterprise. All 2 developments

Within The Icahn School of Medicine at Mount Sinai is part of the Mount Sinai Health System.

The entities involved

Coverage

Newest first; wire copies grouped